Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Affiliation

Maastro Clinic, Department of Radiation Oncology Maastricht, the Netherlands. Electronic address: [Email]

Abstract

Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in pre-clinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in a clinical trial.

Keywords

Cancer immunotherapy,Chemotherapy,Combination treatment,Immune checkpoint inhibitors,NSCLC,Nivolumab,Non-small cell lung cancer,PD-1 inhibitor,Radiotherapy,

OUR Recent Articles